{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:17:15Z","timestamp":1760059035808,"version":"build-2065373602"},"reference-count":52,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Childhood neuroblastoma (NB) is a malignant tumour that is a member of a class of embryonic tumours that have their origins in sympathoadrenal progenitor cells. There are five stages in the clinical NB staging system: 1, 2A, 2B, 3, 4S, and 4. For those diagnosed with stage 4 neuroblastoma (NBS4), the treatment options are limited with a survival rate of between 40 and 50%. Since 1975, more than 15 targets have been identified in the search for a treatment for high-risk NBS4. This article is concerned with the search for a multi-target drug treatment for high-risk NBS4 and focuses on four possible treatment targets that research has identified as having a role in the development of NBS4 and includes the inhibitors Histone Deacetylase (HDAC), Bromodomain (BRD), Hedgehog (HH), and Tropomyosin Kinase (TRK). Computer-aided drug design and molecular modelling have greatly assisted drug discovery in medicinal chemistry. Computational methods such as molecular docking, homology modelling, molecular dynamics, and quantitative structure\u2013activity relationships (QSAR) are frequently used as part of the process for finding new therapeutic drug targets. Relying on these techniques, the authors describe a medicinal chemistry strategy that successfully identified eight compounds (inhibitors) that were thought to be potential inhibitors for each of the four targets listed above. Results revealed that all four targets BRD, HDAC, HH and TRK receptors binding sites share similar amino acid sequencing that ranges from 80 to 100%, offering the possibility of further testing for multi-target drug use. Two additional targets were also tested as part of this work, Retinoic Acid (RA) and c-Src (Csk), which showed similarity (of the binding pocket) across their receptors of 80\u2013100% but lower than 80% for the other four targets. The work for these two targets is the subject of a paper currently in progress.<\/jats:p>","DOI":"10.3390\/molecules30102211","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:37:13Z","timestamp":1747633033000},"page":"2211","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High-Risk Neuroblastoma Stage 4 (NBS4): Developing a Medicinal Chemistry Multi-Target Drug Approach"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1979-9129","authenticated-orcid":false,"given":"Amgad","family":"Gerges","sequence":"first","affiliation":[{"name":"School of Human Sciences, London Metropolitan University, 166-220 Holloway Rd., London N7 8DB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Una","family":"Canning","sequence":"additional","affiliation":[{"name":"Independent Researcher, London SE4 1JT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Cullinane, C.J., Burchill, S.A., Jeremy, A.S., O\u2019Leary, J.J., and Lewis, I.J. (2003). Molecular Biology and Pathology of Paediatric Cancer, Oxford University Press.","DOI":"10.1093\/oso\/9780192630797.001.0001"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/children8060482","article-title":"Novel Treatments and Technologies Applied to the Cure of Neuroblastoma","volume":"8","author":"Paraboschi","year":"2021","journal-title":"Children"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1073\/pnas.72.4.1317","article-title":"Human epidermal growth factor: Isolation and chemical and biological properties","volume":"72","author":"Cohen","year":"1975","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e202300535","DOI":"10.1002\/cmdc.202300535","article-title":"Neuroblastoma and its Target Therapies: A Medicinal Chemistry Review","volume":"19","author":"Gerges","year":"2024","journal-title":"ChemMedChem"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: Progress and challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Inomistova, M., Khranovska, N., and Skachkova, O. (2019). Role of Genetic and Epigenetic Alterations in Pathogenesis of Neuroblastoma, Academic Press.","DOI":"10.1016\/B978-0-12-812005-7.00002-3"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1002\/jcp.30384","article-title":"The quest to develop an effective therapy for neuroblastoma","volume":"236","author":"Bhoopathi","year":"2021","journal-title":"J. Cell Physiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/acs.jcim.6b00491","article-title":"Computational Multitarget Drug Design","volume":"57","author":"Zhang","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: Challenges and Opportunities in Drug Discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrc2787","article-title":"Targeting the cancer kinome through polypharmacology","volume":"10","author":"Knight","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/0929867003375317","article-title":"Molecular Modeling and Computer Aided Drug Design. Examples of their Applications in Medicinal Chemistry","volume":"7","author":"Ooms","year":"2000","journal-title":"Curr. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kumalo, H.M., Bhakat, S., Soliman, M.E.S., Kumalo, H.M., Bhakat, S., and Soliman, M.E.S. (2015). Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls. Molecules, 20.","DOI":"10.3390\/molecules20021984"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1078-0432.CCR-08-0684","article-title":"Histone Deacetylase 8 in Neuroblastoma Tumorigenesis","volume":"15","author":"Oehme","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10188","DOI":"10.1021\/acs.jmedchem.7b01447","article-title":"Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity","volume":"60","author":"Heimburg","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.embor.7401047","article-title":"Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8\u2013substrate complex","volume":"8","author":"Vannini","year":"2007","journal-title":"EMBO Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0092-8674(92)90191-E","article-title":"brahma: A regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2\/SWI2","volume":"68","author":"Tamkun","year":"1992","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/15592294.2016.1265710","article-title":"Bromodomain inhibitors and cancer therapy: From structures to applications","volume":"12","author":"Esteller","year":"2017","journal-title":"Epigenetics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.18632\/oncotarget.6275","article-title":"Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1021\/jm501120z","article-title":"Biased multicomponent reactions to develop novel bromodomain inhibitors","volume":"57","author":"McKeown","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1021\/jm401088k","article-title":"Discovery of epigenetic regulator I-BET762: Lead optimization to afford a clinical candidate inhibitor of the BET bromodomains","volume":"56","author":"Mirguet","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wyce, A., Ganji, G., Smitheman, K.N., Chung, C.-w., Korenchuk, S., Bai, Y., Barbash, O., Le, B., Craggs, P.D., and McCabe, M.T. (2013). BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0072967"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/cmdc.201000011","article-title":"Small-Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics","volume":"5","author":"Peukert","year":"2010","journal-title":"ChemMedChem"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/287795a0","article-title":"Mutations affecting segment number and polarity in Drosophila","volume":"287","author":"Wieschaus","year":"1980","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1126\/science.1098020","article-title":"The Hedgehog Response Network: Sensors, Switches, and Routers","volume":"304","author":"Lum","year":"2004","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.17305\/bjbms.2018.2756","article-title":"The role of the Hedgehog signaling pathway in cancer: A comprehensive review","volume":"18","author":"Skoda","year":"2018","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0896-6273(00)80645-5","article-title":"Hedgehog and patched in neural development and disease","volume":"21","author":"Goodrich","year":"1998","journal-title":"Neuron"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/jco.2010.28.15_suppl.2501","article-title":"A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors","volume":"28","author":"Siu","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrd3753","article-title":"Vismodegib","volume":"11","author":"Dlugosz","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41586-019-1355-4","article-title":"Smoothened stimulation by membrane sterols drives Hedgehog pathway activity","volume":"571","author":"Deshpande","year":"2019","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"24584","DOI":"10.1074\/jbc.M110.131680","article-title":"All Mammalian Hedgehog Proteins Interact with Cell Adhesion Molecule, Down-regulated by Oncogenes (CDO) and Brother of CDO (BOC) in a Conserved Manner","volume":"285","author":"Kavran","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1517\/13543776.2014.910195","article-title":"Tropomyosin receptor kinase inhibitors: A patent update 2009\u20132013","volume":"24","author":"McCarthy","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/13543776.2020.1737011","article-title":"Tropomyosin receptor kinase inhibitors: An updated patent review for 2016\u20132019","volume":"30","author":"Bailey","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2217\/pgs-2019-0064","article-title":"TRK inhibitors: Toward an era of agnostic targeted therapies in oncology","volume":"20","author":"Saleh","year":"2019","journal-title":"Pharmacogenomics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1021\/cn500193f","article-title":"Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: Exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents","volume":"6","author":"Aliaga","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","article-title":"From magic bullets to designed multiple ligands","volume":"9","author":"Morphy","year":"2004","journal-title":"Drug Discov. Today"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10581","DOI":"10.1021\/acs.jmedchem.1c00683","article-title":"Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1758-2946-4-S1-O20","article-title":"Ligand based lead generation\u2014Considering chemical accessibility in rescaffolding approaches via BROOD","volume":"4","author":"Wang","year":"2012","journal-title":"J. Cheminformatics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s10822-012-9584-8","article-title":"FRED and HYBRID docking performance on standardized datasets","volume":"26","author":"McGann","year":"2012","journal-title":"J. Comput.-Aided Mol. Des."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1021\/ci900498n","article-title":"HPPD: Ligand-and Target-Based Virtual Screening on a Herbicide Target","volume":"50","author":"Perruccio","year":"2010","journal-title":"J. Chem. Inf. Model"},{"key":"ref_42","first-page":"1062","article-title":"Improved ligand geometries in crystallographic refinement using AFITT in PHENIX","volume":"72","author":"Janowski","year":"2016","journal-title":"Acta Cryst."},{"key":"ref_43","unstructured":"(VIDA, 2024). VIDA, 5.0.7.0."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/acs.accounts.6b00185","article-title":"Medicinal Chemistry Projects Requiring Imaginative Structure-Based Drug Design Methods","volume":"49","author":"Moitessier","year":"2016","journal-title":"Acc. Chem. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1021\/jm051197e","article-title":"MolDock:\u2009 A New Technique for High-Accuracy Molecular Docking","volume":"49","author":"Thomsen","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_46","unstructured":"(Discovery Studio Visualizer, 2023). Discovery Studio Visualizer, v24.1.0.23298."},{"key":"ref_47","unstructured":"Samson Software (2025, March 20). Protein Aligner. Available online: https:\/\/www.uniprot.org\/align."},{"key":"ref_48","unstructured":"Martin, T., Harten, P., Venkatapathy, R., and Young, D. (2025, March 20). T.E.S.T., EPA-ORD-CCTE Clowder: Public Domain Dedication, 2021, Available online: https:\/\/www.epa.gov\/comptox-tools\/toxicity-estimation-software-tool-test."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Parrot, M., Tajmouati, H., da Silva, V.B.R., Atwood, B.R., Fourcade, R., Gaston-Math\u00e9, Y., Do Huu, N., Perron, Q., Parrot, M., and Tajmouati, H. (2023). Integrating synthetic accessibility with AI-based generative drug design. J. Cheminformatics, 15.","DOI":"10.1186\/s13321-023-00742-8"},{"key":"ref_50","unstructured":"OpenEye, Cadence Molecular Sciences (2023). BROOD, OpenEye."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Horvath, D. (2010). Pharmacophore-Based Virtual Screening. Methods Mol. Biol.","DOI":"10.1007\/978-1-60761-839-3_11"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Korshavn, K.J., Jang, M., Kwak, Y.J., Kochi, A., Vertuani, S., Bhunia, A., Manfredini, S., Ramamoorthy, A., and Lim, M.H. (2015). Reactivity of Metal-Free and Metal-Associated Amyloid-beta with Glycosylated Polyphenols and Their Esterified Derivatives. Sci. Rep., 5.","DOI":"10.1038\/srep17842"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/10\/2211\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:34:59Z","timestamp":1760031299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/10\/2211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["molecules30102211"],"URL":"https:\/\/doi.org\/10.3390\/molecules30102211","relation":{},"ISSN":["1420-3049"],"issn-type":[{"type":"electronic","value":"1420-3049"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}